Evidence map›Paper›PMID 40260662›Full record

ArticleBiomolecules & biomedicine2025

Ansheng Wang, Qiao Ge, Zhenkai Fan, Bing Xia, Zhao Jin, Haitao Liu, Haiwei Sang, Qicai Li, Congli Zhang, Haonan Zhu

Abstract read
In one paragraph

Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ansheng WangDepartment of Thoracic Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Qiao GeDepartment of Thoracic Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Zhenkai FanDepartment of Thoracic Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Bing XiaDepartment of Thoracic Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Zhao JinDepartment of Thoracic Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Haitao LiuDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Haiwei SangDepartment of Thoracic Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Qicai LiDepartment of Thoracic Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Congli ZhangDepartment of Anesthesia, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Haonan ZhuDepartment of Thoracic Surgery, Fuyang People's Hospital, Fuyang, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transforming growth factor β regulator 4 (TBRG4) is upregulated in lung cancer, but its biological role and underlying mechanisms remain poorly understood. In this study, we analyzed pancancer gene expression profiles and clinical data from University of California, Santa Cruz Xena (UCSC Xena) to evaluate the prognostic significance of TBRG4 using univariate and multivariate Cox regression analyses. Genes with a Pearson correlation coefficient above 0.4 with TBRG4 in lung cancer were identified via UALCAN, followed by pathway enrichment analyses to explore their functional associations. To investigate TBRG4's role in lung cancer progression, we assessed cell proliferation, colony formation, and cell cycle alterations in lung cancer cells following TBRG4 knockdown. Western blot analysis was performed to examine the effects of TBRG4 depletion on key cell cycle regulators and epithelial-mesenchymal transition (EMT) markers. Additionally, the biological significance of TBRG4 was evaluated in vivo using a mouse xenograft model. TBRG4 knockdown significantly inhibited cell proliferation and colony formation while inducing cell cycle arrest and apoptosis in lung cancer cells. Analysis of co-expressed genes in the The Cancer Genome Atlas - Lung Adenocarcinoma (TCGA-LUAD) cohort revealed enrichment in cell cycle-related pathways, aligning with our experimental findings. Furthermore, TBRG4 depletion reduced EMT marker expression and suppressed tumor growth in vivo. Collectively, these findings suggest that TBRG4 may serve as a promising prognostic biomarker and therapeutic target in lung cancer.

Indexed as

Biomarkers, TumorCell CycleEpithelial-Mesenchymal TransitionLung NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudePrognosisBiomarkers, Tumor

Identifiers

PMID40260662
PMCPMC12447749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.